Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes.

Author information

Affiliations

  • 1. Division of Clinical Pharmacology, Hokkaido Pharmaceutical University School of Pharmacy, Sapporo, Hokkaido, Japan.
      Authors
    • Senda A 1
    • Mukai Y 1
    • Kato Y 1
    • Toda T 1
    • Inotsume N 1
    (5 authors)
  • 2. Division of Pharmacotherapy, Hokkaido Pharmaceutical University School of Pharmacy, Sapporo, Hokkaido, Japan.
      Authors
    • Hayakawa T 2
    (1 author)
  • 3. Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
      Authors
    • Eliasson E 3
    • Rane A 3
    (2 authors)

ORCIDs linked to this article

Basic & Clinical Pharmacology & Toxicology, 10 May 2017, 121(4):239-245
https://doi.org/10.1111/bcpt.12789 PMID: 28374982 

A comment on this article appears in "Multiple and Opposite Effects of Angiotensin II Receptor Blockers on the Bioavailability of Epoxyeicosatrienoic Acids." Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):213-214.

Abstract 

Cytochrome P450 (CYP) 2C9, CYP2C8 and CYP2J2 enzymes, which metabolize arachidonic acid (AA) to epoxyeicosatrienoic acids, have cardioprotective effects including anti-inflammation and vasodilation. We have recently shown that some angiotensin II receptor blockers (ARBs) may inhibit AA metabolism via CYP2C8. Using recombinant CYP2C9, CYP2J2 and human liver microsomes (HLMs), the aim was now to compare the ability of six different clinically used ARBs to inhibit AA metabolism in vitro. The rank order of the ARBs for the 50% inhibitory concentration (IC50 ) of AA metabolism was losartan <telmisartan <irbesartan <candesartan <olmesartan <valsartan via CYP2C9, and telmisartan <irbesartan <olmesartan <losartan <candesartan and valsartan via CYP2J2. The order for the HLMs was losartan <telmisartan <irbesartan <olmesartan <candesartan <valsartan. Some ARBs having lower concentration of IC50 indicate that these ARBs might inhibit the AA metabolism in the liver.

Full text links 

Read article at publisher's site: https://doi.org/10.1111/bcpt.12789

Read article for free, from open access legal sources, via Unpaywall: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcpt.12789Unpaywall

References 

Articles referenced by this article (48)

Show 10 more references (10 of 48)

Citations & impact 

Impact metrics

8
Citations
Jump to Citations
10
Data citations
Jump to Data

Citations of article over time

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1111/bcpt.12789

Supporting
Mentioning
Contrasting
4
16
0

Article citations

Go to all (8) article citations

Data 

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Japan Society for the Promotion of Science (1)